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Purpose: The optimal dose of gemcitabine that can be used with
concurrent radiation therapy for locally advanced non-small cell lung
cancer has not been well defined. This trial addresses this question in an
alternating sequence “ping-pong” design trial to find the maximum
tolerated dose (MTD) for gemcitabine/carboplatin (Sequence A) or
gemcitabine/paclitaxel (Sequence B) and thoracic radiation therapy
followed by adjuvant gemcitabine/carboplatin chemotherapy.
Patients and Methods: Thirty-five patients with histologically
confirmed Stage IIIA/B non-small cell lung cancer were entered into
two separate sequences, each with multiple cohorts. A dose level
was considered acceptable if, of the first six eligible patients on each
cohort, fewer than three experienced dose limiting toxicities.
Results: Sequence B of this 2 sequence “ping-pong” trial closed
early due to toxicity in cohort 2 (gemcitabine 300 mg/m2/wk and
paclitaxel 30 mg/m2/wk). On Sequence A, the MTD was the cohort
5 dose: gemcitabine 450 mg/m2/wk and carboplatin 2 area under
curve (AUC) concurrently with thoracic radiation. Cohort 7 (gem-
citabine 600 mg/m2/wk and carboplatin 2 AUC) showed 4 dose
limiting toxicities: 2 grade 3 esophagitis; one grade 3 febrile neu-
tropenia; and one grade 4 neutropenia.
Conclusion: Concurrent gemcitabine/paclitaxel chemoradiation
regimen followed by adjuvant gemcitabine/carboplatin produced
excessive toxicity at the lowest tested dose combination and was not
suitable for further study in this trial. Meanwhile, the MTD of
concurrent gemcitabine/carboplatin chemoradiation was determined
to be gemcitabine 450 mg/m2 and carboplatin AUC-2. This combi-
nation was found to be tolerable. Although not a primary end point,
survival results are summarized as well.
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Lung cancer is the most common cause of cancer-relateddeaths in the United States.1 Because of its low cure rate,
lung cancer contributes to more deaths than cancer of the
breast, ovary, and colon combined, and consequently remains
one of the major public health challenges of the current day.
Non-small cell lung cancer (NSCLC) represents three-fourths
of all lung cancer cases, and approximately 25% of these
have a locally advanced presentation (Stage III) that is con-
sidered potentially curable.2 The treatment modalities for
Stage III NSCLC remain controversial and include combina-
tion modalities of surgery, chemotherapy, and radiotherapy.
Before the 1980s, radiotherapy alone was considered
the standard of care for unresectable stage III disease, with
median survival of less than 10 months.3 These low results
led to the development of combined modality treatments
consisting of induction chemotherapy and radiotherapy to
address both local and systemic control of disease. A ran-
domized trial by the Cancer and Leukemia Group B com-
pared standard thoracic radiation therapy for 60 Gy versus
induction chemotherapy with two cycles of cisplatin and
vinblastine followed by thoracic radiation therapy.4 The me-
dian survival time for patients treated with the combination
therapy was 13.8 months versus 9.7 months in the radiation
alone arm. The results of other randomized trials pointed
towards similar increases in median survival as a result of
combined modality treatment.5,6
In the 1990s, randomized trials and a meta-analysis
indicated superior outcomes with concurrent modality ther-
apy compared with sequential therapy.7–11 Although novel
strategies and combinations continue to evolve, relatively few
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have involved the concurrent use of gemcitabine and radia-
tion in unresectable NSCLC.12–14
Gemcitabine is an analog of cytosine arabinoside.15 It is
among a number of new drugs that possess promising single
agent activity in the treatment of NSCLC, including pacli-
taxel, docetaxel, irinocetan, and vinorelbine.16–18 Gemcitab-
ine possesses significant radiosensitizing properties, even at
noncytotoxic concentrations.19,20
Reduction in the 2-deoxyadenosine 5-triphosphate
pool may be one mechanism of radiosensitization. Its phar-
macokinetics, clinical efficacy, toxicity, and administration
have been characterized. The parent nucleoside drug requires
intracellular activation by sequential cellular kinases to its active
form 2,2-difluorodeoxycytidine 5-triphosphate (gemcitabine
triphosphate, dFdCTP). This cytotoxic triphosphate metabo-
lite is retained for long periods within the cell, with terminal
elongation rates of 16 to 72 hours. Therefore, it theoretically
maintains its effects for many hours or even days after
administration, making it an interesting compound to use
simultaneously with daily radiotherapy.
Studies using gemcitabine as single agent therapy have
suggested tolerable doses as high as 1250 mg/m2/wk.15 How-
ever, a phase II study from the European consortium using
weekly gemcitabine at a dose of 1000 mg/m2 with concurrent
thoracic radiation therapy closed early with only 8 patients
due to significant toxicities.11 While the use of gemcitabine in
combination with platinum based chemotherapy for NSCLC
treatment has been fairly well studied, the optimal dose of
gemcitabine for use in concurrent chemoradiation has not
been clearly delineated.
Based on the favorable response rates of gemcitabine
and paclitaxel as single agents in the treatment of inoperable
NSCLC,21–23 as well as their ability to radiosensitize, we
undertook this phase I study to examine the effects of com-
bining these two novel agents together as a concurrent che-
moradiation regimen. These agents possess differing toxicity
profiles and mechanisms of action, and thus make a logical
choice for combination therapy. We chose to study this
combination alongside another widely used platinum doublet
therapy for gemcitabine and carboplatin. The gemcitabine/
carboplatin regimen has mainly been studied as induction and
consolidation therapy, as opposed to a concurrent chemora-
diation regimen. It is our hope to better define the acceptable
dose of gemcitabine and concurrent thoracic radiation treat-
ment, as well as to define the MTDs of these novel regimens
in the treatment of inoperable NSCLC.
PATIENTS AND METHODS
Patient Selection/Eligibility
The detailed patient characteristics are listed in Table 1.
Eligibility stipulated unresectable loco-regionally advanced
NSCLC without evidence of hematogenous metastases,
Stages IIIA, or IIIB, Zubrod performance status 0–1, and
weight loss 10% in the 3 months before diagnosis. Addi-
tional eligibility criteria included forced expiratory volume in
1 second (forced expiratory volume in the 1 second 1000
ml); no pleural effusion on chest radiograph unless it ap-
peared only after a thoracotomy or other invasive procedure
thoracic procedure; serum creatinine level 1.5 mg/dl, he-
moglobin 8.0 g/dl, absolute granulocyte count 2000/l,
platelets 100,000/l, serum bilirubin 1.5 mg/dl and
SGOT 1.5 times the upper limits of normal (unless caused
by documented benign disease). All patients signed a study-
specific consent form in accordance with local institutional
review board and national regulatory guidelines. Ineligibility
criteria included evidence of small cell histology; Stage I, II,
or IV NSCLC; complete or subtotal tumor resection; any
synchronous or prior invasive malignancy (except nonmela-
nomatous skin cancer) unless disease free for 3 years; prior
chemotherapy or thoracic/neck radiation therapy; patients
with myocardial infarction within 6 months or symptomatic
heart disease; and pregnant status for women.
Pretreatment evaluation included a complete medical
history and physical examination; CBC with differential,
platelet count, kidney function and liver function tests, elec-
trolytes and Mg2 within 2 weeks of registration; chest
radiograph; computed tomography (CT) of chest, liver, and
adrenal within 4 weeks; brain CT (or magnetic resonance
imaging) and bone scan within 6 weeks; EKG; and pulmo-
nary function tests including forced vital capacity, forced
expiratory volume in the first second, diffusion capacity for
carbon monoxide within 2 months; a record of location, type,
and size of measurable lesion before treatment; and preg-
nancy tests as applicable within 2 weeks.
Treatment Regimen
This is a phase I study to determine the maximum
tolerated dose (MTD) of two separate regimens for patients
with favorable prognosis, inoperable NSCLC: gemcitabine
and paclitaxel with concurrent RT to 63 Gy, and gemcitabine
and carboplatin with concurrent radiotherapy (RT) to 63 Gy
(Figure 1). Six eligible and evaluable patients were needed
for each cohort in both treatment sequences. Gemcitabine
was given at a starting dose of 300 mg/m2/wk for both
sequences. Conference calls were regularly held with study
chair, coinvestigators, and other participating institutions.
The gemcitabine and carboplatin or gemcitabine and pacli-
taxel were delivered in the outpatient setting as an intrave-
TABLE 1. Pretreatment Characteristics
Cohort
1
(n  7)
Cohort
2
(n  8)
Cohort
3
(n  6)
Cohort
5
(n  7)
Cohort
7
(n  7)
Age
Median 60 63 65.5 67 66
Range 49–72 43–83 52–76 61–72 55–72
n % n % n % n % n %
Gender
Male 6 86 4 50 2 33 5 71 3 43
Female 1 14 4 50 4 67 2 29 4 57
Zubrod
0 2 29 5 63 2 33 5 71 2 29
1 5 71 3 38 4 67 2 29 5 71
n, number.
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nous infusion on days 1, 8, 22, 29, and 43 of the planned
radiation therapy course. Gemcitabine and paclitaxel doses
were escalated per schema until dose-limiting toxicity (DLT)
was determined. Paclitaxel was given at a starting dose of 30
mg/m2/wk, intravenously by 1-hour infusion (in an outpatient
setting) on days 1, 8, 22, 29, and 43 following gemcitabine.
Carboplatin was given at a dose of area under curve (AUC)
2.0 over 30 minutes immediately after gemcitabine on days 1,
8, 22, 29, and 43.
Calculated dose of carboplatin (mg)  target AUC 
(GFR  25); GFR calculated by Cockroft-Gault formula:
GFR ([140 – age][kg wt]) divided by ([serum creatinine]
[72]). The patient was premedicated 30 minutes prior to
paclitaxel with (1) dexamethasone-20 mg IV immediately (or
dexamethasone 20 mg orally 12 and 6 hours prepaclitaxel) in
conjunction with (2) diphenhydramine-50 mg IV and (3)
ranitidine-50 mg IV or cimetidine-300 mg IV or Pepcid at
investigator’s discretion.
Three weeks after the end of the chemoradiation phase
patients began their adjuvant chemotherapy. They received
two cycles of IV gemcitabine-carboplatin. The delivery
schedule was as follows: gemcitabine (G) 1000 mg/m2 IV
days 71, 78  carboplatin AUC 5.5 IV day 71. This cycle
was repeated again after 21 days.
RT was administered at 1.8 Gy once-daily 5 days per
week to a dose of 45 Gy to the primary and mediastinum plus
a boost of 18 Gy in 9 2.0 Gy fractions to the primary and
involved nodes. The boost volume included the primary,
pathologically involved nodes, and nodes2 cm in diameter.
A minimum 2.0 cm margin and maximum 2.5 cm margin
were required in both treatment volumes. The radiation doses
were calculated according to the ICRU recommendations,
without heterogeneity corrections. CT-based treatment plan-
ning was suggested, but not required.
In Sequence A, the gemcitabine and paclitaxel with
concurrent RT regimen, there were five possible escalations
from the initial doses, for a total of six cohorts. In Sequence
B, the gemcitabine and carboplatin with concurrent RT reg-
imen, there were six possible escalations from the initial
doses, for a total of seven cohorts.
Statistical Analysis
The goal of this study was to establish the MTD of each
of the 2 regimens at which no patients developed acute grade
5 toxicity and less than 50% of patients developed acute
DLTs. A DLT was defined as: (1) acute grade 3 or 4
nonhematologic toxicities (acute nonhematologic toxicity is
defined to be a toxicity occurring from day 1 of study entry
to day 1 of adjuvant chemotherapy or within 90 days from the
start of RT treatment, which ever occurs first) or grade 4
hematologic toxicities occurring during concurrent chemora-
diation therapy; (2) grade 3 or 4 pneumonitis or grade 3 or 4
delayed onset esophagitis occurring during the consolidation
phase. Asymptomatic grade 4 hematologic toxicities (e.g.,
neutropenia, thrombocytopenia) occurring during the consol-
idation phase were not considered as DLTs.
Six patients were required per dose cohort to evaluate
for DLTs. Patients were followed for a minimum of 90 days
from the start of radiation therapy. Toxicity was monitored
continuously as each patient was accrued and follow-up data
was accumulated. Acute RT and chemotherapy toxicities
were graded using CTC v 2.0 criteria.24 Late RT toxicities
were reported using the Radiation Therapy Oncology Group/
European Organization for Research and Treatment of Can-
cer Late Toxicity Criteria.25 Only one cohort was open for
accrual at a time, and accrual alternated between cohorts on
the two sequences. Both sequences first tested a dose of 300
g/m2/wk of gemcitabine alone. After evaluation of six eligible
and evaluable patients, a dose was considered acceptable if
fewer than three of the six patients experienced DLTs. If
three or more patients experienced DLTs, the dose was
considered too toxic and the preceding dose declared the
MTD. At a given dose level, the probability of halting dose
escalation when the true toxicity was 50% or higher was at
least 66% (statistical power). In addition, if the true DLT rate
was 20%, there was a 10% probability of halting dose
escalation at a given dose level (type I error).
Frequency tables with counts and percentages were
used to describe pretreatment characteristics, toxicities, com-
pliance review results, and treatment response for each co-
hort. Overall survival (OS) was evaluated. Estimates for OS
were estimated using Kaplan-Meier for each cohort and each
sequence. An event in OS is death due to any cause. OS was
measured from date of study entry to the date of death or last
follow-up. This study was not designed or powered to make
comparisons of efficacy endpoints between dose levels so
only estimates with 95% confidence intervals are provided.
Sequence A * Sequence B * (closed 5/22/03) 
Gemcitabine
Dose
(mg/m2/wkly)
Carboplatin 
Dose
(AUC)
Number of 
Patients 
Gemcitabine
Dose
(mg/m2/wkly)
Paclitaxel 
Dose
(mg/m2/wkly)
Number of 
Patients 
Cohort 1: 300 -- 6 Cohort 2: 300 30 6
Cohort 3: 300 2 6 Cohort 4: 450 30 6
Cohort 5: 450 2 6 Cohort 6: 450 40 6
Cohort 7: 600 2 6 Cohort 8: 600 40 6
Cohort 9: 750 2 6 Cohort 10: 600 50 6
Cohort 11: 900 2 6 Cohort 12: 750 50 6
   Cohort 14: 900 50 6
Day 1 Day 8 Day 15 Day 22 Day 29 Day 36 Day 43 
(Cohort 1) RT XXXXX XXXXX XXXXX XXXXX XXXXX XXXXX XXXX 
Chemo G G  G G  G 
(Cohorts 2-14) RT XXXXX XXXXX XXXXX XXXXX XXXXX XXXXX XXXX 
Chemo G/C or G/P G/C or G/P  G/C or G/P G/C or G/P  G/C or G/P 
All Cohorts Following RT Day 71 Day 78 Day 85 Day 92 Day 99 Day 106  
Chemo  C + G G  C + G G   
FIGURE 1. Treatment schema. G,
gemcitabine; C, carboplatin; P, pacli-
taxel; AUC, area under curve.
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RESULTS
The study opened on April 30, 2001 and closed on
April 12, 2005 after accruing a total of 35 patients treated
with 5 different dose levels. Of the 35 patients entered, all
were eligible and evaluable. Pretreatment characteristics for
all eligible/evaluable patients are listed in Table 1. The
median ages of patients on cohorts 1 and 2 (60 and 63 years,
respectively) was lower than the median ages of patients on
cohorts 3, 5, and 7 (65.5, 67, and 66, respectively). The
percentage of men on each cohort varied from 33 to 86%, not
unusual since the number of patients on each cohort was
fairly small. Likewise, the percentage of patients with a
Zubrod score of 0 ranged from 29 to 71%.
Toxicities for all eligible/analyzable patients are re-
ported in Tables 2, 3. Individual patients can have more than
one DLT. There were 2 DLTs in Sequenced A, cohort 1:
grade 3 esophagitis and grade 4 neutropenia. Two cases on
cohort 2 (the first level of Sequence B) had DLTs: grade 3
pneumonitis and grade 3 dehydration. One additional patient,
however, experienced a late grade 4 tracheoesophageal fistula
and subsequently died; the death was reported and verified as
treatment-related. As a result, Sequence B was closed on May
22, 2003 due to excessive toxicity. There were only 2 DLTS
on cohort 3 of Sequence A (grade 3 and grade 4 esophagitis)
so this dose was considered acceptable. There were also only
2 DLTs reported on cohort 5 (grade 4 neutropenia and grade
3 esophagitis). In cohort 7, there were 4 DLTs (grade 3
esophagitis; grade 4 decrease platelet count; grade 3 esoph-
agitis; and grade 4 neutropenia). This exceeded the maximum
number of DLTs allowed for acceptable toxicity. Conse-
quently, the MTD on Sequence A was determined to be 450
mg/m2/wk of gemcitabine and carboplatin at 2 AUC concur-
TABLE 2. Chemotherapy and Acute Radiotherapy Toxicity (CTC v 2.0 Criteria)
Cohort 1
(n  7)
Grade
Cohort 2
(n  8)
Grade
Cohort 3
(n  6)
Grade
Cohort 5
(n  7)
Grade
Cohort 7
(n  7)
Grade
Category 3 4 3 4 3 4 3 4 3 4
Allergy/immunology 0 0 1 0 0 0 0 0 0 0
Blood/bone marrow 3 1 5 2 3 1 2 3 4 3
Cardiovascular (arrhythmia) 0 0 0 0 0 0 0 0 1 0
Cardiovascular (general) 0 0 1 0 0 0 0 0 2 0
Constitutional symptoms 0 0 1 0 1 0 0 0 1 0
Dermatology/skin 0 0 2 0 0 0 1 0 0 0
GI–esophagus 2 0 2 1 1 1 1 0 3 1
Hepatic 1 0 0 0 1 0 1 0 0 0
Infection/febrile neutropenia 0 0 2 0 0 0 0 0 1 0
Metabolic/laboratory 0 0 0 0 0 0 0 0 2 0
Neurology 0 0 1 0 0 0 0 1 1 0
Pain 1 0 1 0 0 0 0 0 1 1
Pulmonary 0 0 1 1 0 0 0 0 0 0
Worst nonhematologic 3 (43%) 0 (0%) 5 (63%) 2 (25%) 2 (33%) 1 (17%) 2 (29%) 1 (14%) 4 (57%) 2 (29%)
Worst overall 5 (71%) 1 (14%) 5 (63%) 3 (38%) 3 (50%) 2 (33%) 2 (29%) 4 (57%) 3 (43%) 4 (57%)
CTC, common toxicity criteria; n, number.
TABLE 3. Late Radiotherapy Toxicity (RTOG/EORTC Late Toxicity Criteria)
Cohort 1
(n  6)
Grade
Cohort 2
(n  6)
Grade
Cohort 3
(n  6)
Grade
Cohort 5
(n  5)
Grade
Cohort 7
(n  7)
Grade
3 4 3 4 5 3 4 3 4 3 4
Esophagus 0 0 1 0 1 0 1 0 0 1 0
Skin (within the
irradiated field)
0 0 0 0 0 0 0 0 0 0 0
Lung 0 0 1 0 0 0 1 0 0 2 0
Heart 0 0 0 0 0 0 0 0 0 0 0
Subcutaneous tissue 0 0 0 0 0 0 0 0 0 0 0
Spinal cord 0 0 0 0 0 0 0 0 0 0 0
Bone 0 0 0 0 0 0 0 0 0 0 0
Other 0 0 0 0 0 0 0 0 0 0 0
Worst overall 0 (0%) 0 (0%) 2 (33%) 0 (0%) 1 (17%) 0 (0%) 1 (17%) 0 (0%) 0 (0%) 2 (29%) 0 (0%)
RTOG, Radiation Therapy Oncology Group; EORTC, European Organization for Research and Treatment of Cancer; n, number.
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rently with radiation therapy at 1.8 Gy/5 days a week for 5
weeks followed by 2 Gy/5 days a week for 9 fractions (total
dose of 63 Gy).
Thirty (86%) patients had an RT review of per protocol
or acceptable variation. Fifty-seven percent of patients during
the concurrent phase were per protocol on both their RT and
chemotherapy reviews. Compliance in the consolidation
phase was slightly lower, with 54% of cases being per
protocol on their RT and chemotherapy reviews.
Response and survival outcome results are shown in
Tables 4. On Sequence A, 74% of patients experienced a
complete or partial response (20 of 27), with 6 complete
responses reported. On Sequence B, 5 of the 8 patients had a
complete or partial response, with 2 complete responses
(Table 4). Median follow-up time for all patients was 15.9
months on cohort 1; 12.9 months on cohort 2; 16.1 months on
cohort 3; 12.4 months on cohort 5; and 13.3 months on cohort
7. MST in both sequences is similar: 13.3 months in Se-
quence A and 12.9 months in Sequence B (Table 5).
DISCUSSION
The treatment of Stage III NSCLC presents a signifi-
cant therapeutic dilemma to the clinician. Depending on the
tumor presentation and anatomic involvement, multiple mo-
dalities can be used. In the treatment of inoperable NSCLC,
it is generally accepted that a concurrent chemoradiation
paradigm is the standard of care. However, the combinations
of concurrent chemoradiation with induction therapy and
consolidation therapy are many, and there is no one univer-
sally accepted regimen of concurrent chemoradiation em-
ployed to treat NSCLC. The aim of this study was to better
characterize the optimal dose of gemcitabine in concurrent
chemoradiation therapy, as well as to investigate the MTDs
of a gemcitabine/paclitaxel regimen concurrent with thoracic
radiation and adjuvant chemotherapy as well as gemcitabine/
carboplatin concurrent with thoracic radiation and adjuvant
chemotherapy in favorable prognosis, inoperable Stage
IIIA/B NSCLC.
We designed this trial as a “ping-pong” trial that ac-
crued patients in cohorts of two separate sequences in an
alternating fashion. After a cohort fully accrued on sequence
A, accrual then began for a cohort on sequence B. The
rationale for this design was to continue accrual of patients on
the study protocol while a previous cohort was being ana-
lyzed for DLT before dose escalation within a sequence.
Enrollment first occurred in a treatment cohort to verify
tolerance of gemcitabine 300 mg/m2/wk concurrent with
thoracic radiation before subsequent patient enrollment in
either sequence A or B combining gemcitabine with either
carboplatin or paclitaxel.
A meta-analysis from Pritchard et al.26 suggests that
traditional platinum-based chemotherapy combined with RT
adds an average of 2 months to patient survival. Several
phase I and II trials have looked at the combination of
gemcitabine and carboplatin in NSCLC.27 A regimen devel-
oped by Edelmen et al.28 used gemcitabine 1000 mg/m2 on
day 1,8 and carboplatin AUC 5.5 on day 8 on a q3 weekly
basis followed by single agent paclitaxel and was well toler-
ated with a 31% response rate and a 10-month median
survival. This gemcitabine/carboplatin combination regimen
(and minor variations thereof) has been used for induction
and consolidation therapy in combined modality treatment for
NSCLC and is well tolerated.29,30 In this study, we employed
consolidative therapy according to this regimen. However,
there have been no definitive studies involving and/or estab-
lishing the use of gemcitabine and carboplatin concurrent
with radiation therapy for NSCLC. Our results indicate that a
gemcitabine/carboplatin combination concurrent with tho-
racic radiation is well tolerated up to cohort 5 of our trial,
with a MTD of gemcitabine 450 mg/m2/wk and carboplatin 2
TABLE 4. Best Observed Response
Cohort 1
(n  7)
Cohort 2
(n  8)
Cohort 3
(n  6)
Cohort 5
(n  7)
Cohort 7
(n  7)
n % n % n % n % n %
Complete response 1 14 2 25 3 50 2 29 0 0
Partial response 4 57 3 38 2 33 4 57 4 57
Stable disease 0 0 1 13 1 17 0 0 1 14
Progressive disease 2 29 1 13 0 0 1 14 1 14
Unknown 0 0 1 13 0 0 0 0 1 14
n, number.
TABLE 5. Overall Survival by Sequence
Time (mo)
Sequence A
(n  27)
Sequence B
(n  8)
Survival (%)
(95% CI)
No.
at Risk
Survival (%)
(95% CI)
No.
at Risk
0 100 27 100 8
6 81 (61–92) 22 63 (23–86) 5
12 63 (42–78) 17 50 (15–77) 4
18 44 (26–62) 12 25 (4–56) 2
24 30 (14–47) 8 25 (4–56) 2
30 26 (11–43) 6 25 (4–56) 2
Median survival
time
13.3 12.9
Dead/total 22/276/8
Median follow-up
time (range)
13.3 (1.6–59.0) 12.9 (3.0–58.4)
CI, confidence interval, n, number.
Choy et al. Journal of Thoracic Oncology • Volume 4, Number 1, January 2009
Copyright © 2008 by the International Association for the Study of Lung Cancer84
AUC concurrent with thoracic radiation to 63 Gy and adju-
vant gemcitabine/carboplatin chemotherapy. The acute tox-
icities of concurrent chemoradiation with gemcitabine and
carboplatin were acceptable, including a grade 4 neutropenia
and grade 3 esophagitis.
Sequence B of this study was closed on May 22, 2003
because of excessive toxicity in the first cohort of this
sequence, cohort 2 (gemcitabine 300 mg/m2/wk and pacli-
taxel 30 mg/m2/wk). The toxicities included a grade 3 pneu-
monitis, grade 3 dehydration, and a late grade 4 tracheo-
esophageal fistula that subsequently resulted in the patient’s
death. Although no patients developed acute grade 5 toxicity,
the number of DLTs exceeded the allowable limit for dose
escalation. These data suggest that a gemcitabine/paclitaxel
combination is not suitable with concurrent thoracic radiation
therapy. Combined gemcitabine 300 mg/m2/wk and carbo-
platin 2 AUC was well tolerated. The excessive toxicity seen
when combining gemcitabine 300 mg/m2/wk and paclitaxel
30 mg/m2/wk suggests a possible synergy between gemcit-
abine and paclitaxel. While such a synergy may lead to more
effective treatment, it can also potentially cause synergistic
toxicity in the presence of RT. The MST in both sequences
was similarly lower than anticipated in this patient population
with concurrent chemoradiation therapy (13.3 months in
Sequence A and 12.9 months in Sequence B), although
survival was not a primary end point of this trial.
CONCLUSION
Multiple trials have shown evidence that combined
concurrent modality therapy is more effective in treating
NSCLC than sequential therapy. The distinct features of our
NSCLC study involved using novel combinations of rela-
tively newer chemotherapeutic agents that possess radiosen-
sitizing properties in combination with concurrent thoracic
radiation treatment. The unique “ping-pong” design of the
trial allowed for the testing of two different regimens in a
stepwise manner thus ensuring no breaks in accrual for the
dose escalation sequences. Concurrent therapy is superior
over sequential therapy due to the greater simultaneous con-
trol of local disease synergistic with radiation, as well as
control of micrometastatic disease. To date, there is no
definitive evidence that establishes the superiority of induc-
tion chemotherapy or consolidation chemotherapy in the
setting of concurrent chemoradiation. We undertook this
study to elucidate the MTDs of concurrent chemoradiation
regimens in the absence of induction chemotherapy, and
opted to treat potential systemic disease adjuvantly with
established full dose cycles of gemcitabine and carboplatin.
In conclusion, we report the MTD of gemcitabine and car-
boplatin in the setting of concurrent chemoradiation. This
regimen may be considered for further efficacy investigation
in a larger trial setting.
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